Market Survey on Persistent Epithelial Defect Management Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Persistent Epithelial Defect Management Market including Epithelial/Limbal, Inflammatory Disease, and Neurotrophic Disease Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Persistent Epithelial Defect Management Market Snapshot (2023 to 2033)
The global persistent epithelial defect management market is slated to reach a valuation of US$ 8.5 billion in 2023. According to Future Market Insights, the market is expected to grow at an 18% CAGR until 2033, being valued at US$ 44.49 billion.
The persistent epithelial defect (PED) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted PED symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Persistent Epithelial Defect (PED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Persistent epithelial defects (PEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. In recent years, PED awareness has increased with increased research activities from various spectrums of ophthalmology research. However, the actual frequency of PED is not known as of now, but some studies have estimated the frequency based on the causative occurrence of the disease with underlying conditions.
Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect, and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others.
The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Disruptions in this protective layer can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and decreased visual acuity.
It covers the details of conventional and current medical therapies and diagnoses available in the persistent epithelial defect (PED) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Persistent Epithelial Defect (PED) market report gives a thorough understanding of PED symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PED symptoms of treatment algorithms and treatment guidelines for PED symptoms in the US, Europe, and Japan.
Attributes
Details
Expected Market Value (2023)
US$ 8.5 billion
Projected Forecast Value (2033)
US$ 44.49 billion
Global Growth Rate (2023 to 2033)
18%
Forecast period
2023 to 2033
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 To 2022 Persistent Epithelial Defect Management Market Demand Analysis Vs. Forecast 2023 to 2033
The global persistent epithelial defect management market is expected to surge at a CAGR of 18% for the forecast period compared to the historic CAGR from 2018 to 2022 of 19.3%, as per Future Market Insights, a provider of market research and com compared to the competitive intelligence.
Patients usually present with pain, watering, and foreign body sensation in the affected eye. However, these features may be absent in neurotrophic PEDs. There may be blurring of vision, redness, photophobia, pain with blinking, and eye movements. PED, if left untreated, can lead to corneal inflammation, infection, ulceration, scarring, melting, and even perforation due to disruption of the protective epithelial and stromal layers of the cornea.
A comprehensive history comprising duration, mechanism of trauma, prior treatment received and surgeries, associated ocular and systemic comorbidities, family history, and immune status will help arrive at an etiological diagnosis and allow more specific treatment. Distinguishing an epithelial defect from a PED can be done based on the time required for complete healing after an injury. An epithelial defect recovers by 7 to 10 days, while a PED will not heal even after two weeks, and such a patient is usually refractory to standard treatments and supportive care
But nowadays, a thorough examination of both the eyes, adnexa, and systemic assessment is of utmost importance to determine the etiology. Fluorescein staining is used to photograph the defect for serial monitoring and measuring the size, depth, and location of the epithelial defect using a slit lamp. Deeper PEDs take longer to absorb the fluorescein into the stroma and frequently have grayish-white edges with heaped-up epithelium. Associated signs of infection, such as underlying haze and infiltrates and anterior chamber inflammation, must be actively sought. There can be associated basement membrane dystrophies, nodular degeneration, dendrites, limbal stem cell deficiency, conjunctival injection, features of superior limbic keratoconjunctivitis, allergic conjunctivitis, foreign body, and concretions. It is essential to assess dry eyes using the Schirmer test and tear-film breakup time. The Rose Bengal dye stains devitalized epithelial cells, implying impaired tear function, regardless of gross tear flow.
The diagnosis of PED is primarily clinical. It can be supplemented by investigations that help to quantify the lesion and track its progress. AS-OCT is a non-invasive definitive technique for quantifying epithelial thickness and loss over time, especially in areas of corneal thinning and scarring. Confocal microscopy is a technique that allows the imaging of thin layers of living corneal cellular structures in real time. In vivo HRT-II confocal microscopy has been designed for studying the superficial and peripheral corneal and conjunctival epithelium.
For systemic comorbidities, relevant systemic investigations must be conducted. For example, in patients with diabetes, fasting and postprandial blood sugar levels and HbA1C values are measured. Vitamin A deficiency can be confirmed by measuring serum retinol-binding protein and zinc levels. Rheumatoid factor, anti-cyclic citrullinated peptide (anti-CCP) antibody for rheumatoid arthritis, antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) antibody for systemic lupus erythematosus (SLE), anti-Ro/SSA, and anti-La/SSB antibody for Sjogren syndrome are all autoimmune indicators.
The increasing partnerships and collaborations between numerous companies boost market growth. For instance, in October 2017, Bio-Tissue entered a strategic agreement with Optima Pharmazeutische GmbH, a pharmaceutical company that offers otorhinolaryngology, ophthalmology, and pneumology products. This agreement helps the company to distribute its Natural Ocular Cleanser in Germany. Thus, all these collaborations boost the growth of the market.
Higher Demand for Hospitals
The increasing demand for hospitals surges the market grows rapidly. Most chronic disease diagnostics are majorly performed in hospitals since they are very complex and it requires technologically advanced products and thus this is boosting the market for hospital/clinical laboratories.
Find your sweet spots for generating winning opportunities in this market.
What Could Possibly Hinder Persistent Epithelial Defect Management Market Demand?
Lack of skilled professionals
The lack of qualified healthcare professionals who cannot treat the patients with appropriate treatments could reduce the growth of the persistent corneal epithelial defect treatment market over a forecast period.
High Cost of Treatment
The enormous expenditure that is required for setting up these techniques hinders market growth. Numerous market players make huge investments in installing new and advanced machines to faster the process and in return, the cost is increased.
This persistent corneal epithelial defects treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
Region-wise Analysis
What Is the Outlook of the North American Persistent Epithelial Defect Management Market?
The presence of key players and increasing initiatives are accelerating the growth
North America’s persistent epithelial defects treatment market is expected to witness significant growth during the forecast period. Although numerous therapies exist and a growing number of novel approaches are evolving, treatment of this disease can still be quite challenging.
It is necessary to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. The introduction of the latest technology development which offers various therapies for treating various complications caused by the disorder and the rise in the incidence of dry eye syndrome boosts the market growth.
The market in North America was valued at US$ 98.8 million in 2021. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Future Market Insights team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
What Can Be Expected from The European Persistent Epithelial Defect Management Market for Treatment?
The persistent epithelial defects treatment market is projected to witness significant growth during the forecast period. Although several therapies exist and an increasing number of novel approaches are evolving, treatment of this disease can still be quite challenging. It is essential to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing.
The introduction of the latest technology development offers numerous therapies for treating several complications caused by the disorder and the increase in the incidence of market growth. The expected CAGR of the persistent epithelial defects treatment market in Europe is likely to amount to 17.8% from 2023 to 2033.
What Can Be Expected from The Asia Pacific Persistent Epithelial Defect Management Market for Treatment?
The Asia-Pacific persistent epithelial defects treatment market is projected to witness significant growth during the forecast period. Although several therapies exist and an increasing number of novel approaches are evolving, treatment of this disease can still be quite challenging. It is essential to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing.
The introduction of the latest technology development offers numerous therapies for treating several complications caused by the disorder and the increase in the incidence of market growth. A growth rate in the persistent epithelial defects treatment market in the forecast period 2023-2033. The expected CAGR in the Asia Pacific is expected to be around 17.7% in the mentioned forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Type of Persistent Epithelial Defect Management Market Treatment is Most Prevalent?
The epithelial/limber segment will gain the dominant market share
Over the course of the forecast period, the epithelial/limber segment of disease type is anticipated to occupy a significant share of the global persistent epithelial defect management treatment market. In 2023, this category is also anticipated to acquire revenue share.
Due to their superior therapeutic activity, the epithelial/limber segment subgroup of disease types occupies a leading position in the worldwide persistent epithelial defect market. This is so because, epithelial cell migration and corneal epithelial stem cells in the limbus are crucial to regenerate the tissue after an insult to the corneal epithelium. Therefore, limbal stem cell deficiency (LSCD) often results in the inability of epithelial regeneration, stromal melting, scarring, persistent epithelial defects, corneal conjunctivalization, and neovascularization.
One of the common causes of severe limbal stem cell deficiency is an alkali-induced chemical injury from lye, household cleaning solutions, and fertilizers. Such factors are expected to accelerate the growth prospects for persistent epithelial defect management treatment from 2023 to 2033. The way to cure epithelial/limber disease is when the limbal stem cell deficiency has not yet fully developed, it can be treated with eye drops. However, in severe cases, limbal stem cell transplantation is regarded as the best option.
Which Distribution Channel is expected to gain traction from 2023 to 2033?
The demand for hospital/clinical laboratories will be more during the forecast period.
According to a report by Future Market Insights, the hospital/clinical laboratories would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to epithelial/limber disease, the hospital/clinical laboratory sector is anticipated to dominate the worldwide persistent epithelial defect management market.
As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
How Competitive is the Market for Persistent Epithelial Defect Management Treatment?
The persistent epithelial defects management treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the persistent corneal epithelial defects treatment market.
Some of the important developments of the key players in the market are
Kala Pharmaceuticals acquired Combangio, expanding its pipeline with a clinical-stage novel biologic for the treatment of Persistent Epithelial Defect (PED) and other rare ocular surface diseases.
Nexagon has a market advantage in the US, as it received orphan drug designation from the FDA. It is being developed by OcuNexus Therapeutics in partnership with Eyevance Pharmaceuticals. Currently, the drug is under phase II studies for PED.
Key players operating in the persistent epithelial defects treatment market t include
Dompe Farmaceutici
OcuNexus Therapeutics
Eyevance Pharmaceuticals
Noveome Biotherapeutics
RegeneRx Biopharmaceuticals
Recordati Rare Diseases
Mimetech
Johnson & Johnson Services Inc.
Bausch Health Companies Inc.
Integra Lifesciences
Report Scope
Report Attribute
Details
Growth Rate
18% CAGR
Base Year Estimation
2022
Market Value in 2023
US$ 8.5 billion
Market Value in 2033
US$ 44.49 billion
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
US$ billion for Value and CAGR from 2023 to 2033
Reports Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Disease Type
End User
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
United Kingdom
Spain
Germany
Italy
France
China
Japan
South Korea
India
Malaysia
Singapore
Thailand
South Africa
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Dompe Farmaceutici
OcuNexus Therapeutics
Eyevance Pharmaceuticals
Noveome Biotherapeutics
RegeneRx Biopharmaceuticals
Recordati Rare Diseases
Mimetech
Johnson & Johnson Services Inc.
Bausch Health Companies Inc.
Integra Lifesciences
Customization Scope
Available on Request
Key Segments Profiled in the Persistent Epithelial Defect Management Market Report
Disease Type:
Epithelial/Limbal
Inflammatory Disease
Neurotrophic Disease
Others
End User:
Hospitals/Clinical Laboratories
Physician Offices
Reference Laboratories
Other End Users
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the Current Persistent Epithelial Defect Management Market Valuation?
The market is estimated to secure a valuation of US$ 8.5 billion in 2023.
Which Countries Dominate the Global Market?
The United States, Japan, and China dominate the global market.
Which Country is Set to Register Exponential Growth in Persistent Epithelial Defect Management Market?
The United States may witness significant growth in the market.
What is the Growth Forecast for Persistent Epithelial Defect Management Market?
The market is forecast to register a CAGR of 18% through 2033.
What is the Projected Size of the Market by 2033?
The global market size will reach US$ 44.49 billion by 2033.
Table of Content
1. Executive Summary | Persistent Epithelial Defect Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
5.3.1. Epithelial/limbal
5.3.2. Inflammatory disease
5.3.3. Neurotrophic disease
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospital/Clinical Laboratories
6.3.2. Physician Offices
6.3.3. Reference Laboratories
6.3.4. Other End Users
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. Middle East & Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Disease Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Disease Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Disease Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Disease Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By End User
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Disease Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By End User
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Disease Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By End User
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Disease Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By End User
13.4. Key Takeaways
14. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of Middle East & Africa
14.2.2. By Disease Type
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Disease Type
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Disease Type
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Disease Type
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Disease Type
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Disease Type
15.5.2.2. By End User
15.6. United kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Disease Type
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Disease Type
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Disease Type
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Disease Type
15.9.2.2. By End User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Disease Type
15.10.2.2. By End User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Disease Type
15.11.2.2. By End User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Disease Type
15.12.2.2. By End User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Disease Type
15.13.2.2. By End User
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Disease Type
15.14.2.2. By End User
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Disease Type
15.15.2.2. By End User
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Disease Type
15.16.2.2. By End User
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Disease Type
15.17.2.2. By End User
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Disease Type
15.18.2.2. By End User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Disease Type
15.19.2.2. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Disease Type
15.20.2.2. By End User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Disease Type
15.21.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Disease Type
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Dompe Farmaceutici
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. OcuNexus Therapeutics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Eyevance Pharmaceuticals
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Noveome Biotherapeutics
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. RegeneRx Biopharmaceuticals
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Recordati Rare Diseases
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Mimetech
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Johnson & Johnson Services, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Bausch Health Companies Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Integra Lifesciences
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 13: Global Market Attractiveness by Disease Type, 2023 to 2033
Figure 14: Global Market Attractiveness by End User, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 28: North America Market Attractiveness by Disease Type, 2023 to 2033
Figure 29: North America Market Attractiveness by End User, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Disease Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 58: Europe Market Attractiveness by Disease Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by End User, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Disease Type, 2023 to 2033
Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MEA Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MEA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 113: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 114: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 118: MEA Market Attractiveness by Disease Type, 2023 to 2033
Figure 119: MEA Market Attractiveness by End User, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
